KANSAS CITY, Mo.--(BUSINESS WIRE)--ARJ Infusion Services will dispense and administer bamlanivimab, a monoclonal antibody drug to treat COVID-19. ARJ will dispense treatments to eligible high-risk individuals residing or working in assisted living and long-term care facilities.
Bamlanivimab is authorized for use against mild-to-moderate COVID-19 in children and adults, including adults over 65. To be eligible, patients must not be hospitalized and be within 10 days of the onset of COVID-19 symptoms, at least 12 years of age, and at high risk for an escalation of symptoms. Patients can receive therapy following a positive diagnosis.
ARJ will dispense the medication and perform infusions within 24 hours of receiving and authorizing physician orders. Treatment will be available at no out-of-pocket cost to the patient.
“ARJ is on the frontlines of the COVID-19 pandemic to serve patients with rare and severe chronic conditions,” said Andy Copeland, Chief Executive Officer of ARJ Infusion Services. “We are proud to collaborate with NHIA to ensure optimal infusion treatments and play our part in increasing access to quality care for our most vulnerable populations.”
With over two decades of delivering and administering intravenous products, ARJ pharmacists and nurses provide healthcare organizations with safe, quality clinical care and support.
To enroll in infusion services, please visit arjinfusion.com/speed.
About ARJ Infusion Services
ARJ Infusion Services is a nationwide industry leader in specialty pharmacy and in-home nursing services for children and adults with rare and chronic conditions. ARJ’s specialty pharmacy expertise provides safe clinical monitoring and administration of complex infusion therapies.
Learn more or enroll a patient at arjinfusion.com/speed.
